Professionals 214 Users Online

Progressive Multifocal Leukoencephalopathy Treatment Market

Global Market Study on Progressive Multifocal Leukoencephalopathy Treatment: HIV/AIDS Indication to Dominate in Terms of Value Through 2026 Owing to Government Initiatives and Support for HIV Associated PML Treatment

Progressive Multifocal Leukoencephalopathy Treatment Market Anti-retroviral Therapy, Antiviral/anti JCV Drugs with HIV/AIDS, Organ Transplantation, Multiple Sclerosis, and Hematological Malignancies Indication

Introduction

Progressive multifocal leukoencephalopathy (PML) is a rare viral disease characterized by progressive damage to the white matter of the brain at different locations. Progressive multifocal leukoencephalopathy destroys the brain cells that produce the protective coating (myelin) of the CNS. PML is active in about 2–6% of the people living with AIDS, generally in patients whose CD4 count is well below 100.

Besides, the number of patients being recognized in the context of immunosuppressive therapies for autoimmune diseases is increasing. Furthermore, the prevalence of chronic but asymptomatic JCV infection in the general population is high. PML also occurs in patients suffering from hematological malignancies, multiple sclerosis and in patients with organ transplant.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Market Value and Forecast

The global progressive multifocal leukoencephalopathy treatment market is projected to grow at a CAGR of 2.8% throughout the forecast period (2018–2026).

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

Progressive Multifocal Leukoencephalopathy Treatment Market: Key Insights

  • Growing prevalence of HIV infection in several middle- and low-income economies is consequently expected to drive the growth of the market for progressive multifocal leukoencephalopathy treatment over the forecast period.
  • Growing prevalence of hematological malignancy and diagnosis of progressive multifocal leukoencephalopathy is expected to drive the growth of the progressive multifocal leukoencephalopathy treatment market over the forecast period.
  • Favorable reimbursements for HIV and cancer treatment is expected to drive the growth of the progressive multifocal leukoencephalopathy market over the forecast period.
  • Emerging treatment options such as use of anti-retroviral and antivirals are expected create lucrative growth opportunities for the new players entering the progressive multifocal leukoencephalopathy treatment market.
  • Enhancement in the testing for HIV and treatment as well as progressive multifocal leukoencephalopathy diagnosis and treatment along with the improvement in healthcare facilities and government programs is expected to spur the growth of the market for progressive multifocal leukoencephalopathy treatment over the forecast period.
  • North America, followed by Europe, is expected to be the leading regional market for progressive multifocal leukoencephalopathy treatment, owing to growing prevalence of HIV infection and hematological malignancies along with progressive multifocal leukoencephalopathy.
  • Growing awareness regarding the treatment of progressive multifocal leukoencephalopathy in underdeveloped countries such as Africa is expected to drive the growth of the market for progressive multifocal leukoencephalopathy treatment over the forecast period.
  • Asia-Pacific progressive multifocal leukoencephalopathy treatment market is projected to have continuous growth over the forecast period due to increasing prevalence of HIV infection and improving treatment rate for HIV and cancer.
  • Improving treatment-seeking rate in middle- and low-income economies and access to safe and effective treatment and timely and accurate diagnosis of cancer is further expected to increase the rate of diagnosis of progressive multifocal leukoencephalopathy
  • Use of antiviral agents, immune response modulators and immunization treatment for the potential population of progressive multifocal leukoencephalopathy is also expected to drive the growth of the market for progressive multifocal leukoencephalopathy treatment in the near future
  • Growing emphasis on the research and development of drugs and therapies for rare disease creates a huge opportunity for the market of progressive multifocal leukoencephalopathy treatment
  • Companies are trying to investigate innovative therapies aimed at control of JC virus infection instead of improving immunity which is projected to spur the growth of the progressive multifocal leukoencephalopathy treatment market over the forecast period
  • The leading companies operating in the progressive multifocal leukoencephalopathy treatment market are focusing on the improvement of the treatment available
Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Progressive Multifocal Leukoencephalopathy Treatment Market: Regional Outlook

The global progressive multifocal leukoencephalopathy treatment market is segmented into five key regions, namely North America, Latin America, Europe, and Asia Pacific and the Middle East & Africa.

In terms of value, North America is expected to be the leading regional market for progressive multifocal leukoencephalopathy treatment and is expected to have significant growth during the forecast period. The Asia Pacific progressive multifocal leukoencephalopathy treatment market is projected exhibit significant growth over the forecast period due to increasing prevalence of HIV infection and progressive multifocal leukoencephalopathy in the region, particularly in China and India.

progressive-multifocal-leukoencephalopathy-treatment-market.jpg

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Progressive Multifocal Leukoencephalopathy Treatment Market: Key Players

Examples of some of the key players operating in the global progressive multifocal leukoencephalopathy treatment market are Pfizer, Inc., GlaxoSmithKline Plc, Sanofi S.A., Gilead Sciences, Inc., Allergan Plc. (Actavis Plc.), Novartis AG, F. Hoffman - La Roche Ltd., AbbVie Inc. and Bristol-Myers Squibb Company, among others.

- Companies Covered in This Report -

  • Pfizer, Inc.
  • F. Hoffman - La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Allergan plc (Actavis plc)
  • Overview
  • Novartis AG
  • Mylan N.V.
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Others.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate